← Back to Search

Monoclonal Antibodies

HPN217 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Harpoon Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Resolved acute effects of any prior therapy to baseline severity or Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade ≤1.
Received at least 3 prior therapies (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody; patients should not be a candidate for or be intolerant of all established therapies known to provide clinical benefit in multiple myeloma).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and tolerated by patients with a certain type of cancer.

Who is the study for?
Adults over 18 with relapsed/refractory multiple myeloma who've had at least three prior treatments, including specific inhibitors and antibodies, and have measurable disease. Not for those with plasma cell leukemia, non-secretory myeloma without measurable disease, recent transplants or autoimmune diseases (with some exceptions), or a second primary malignancy not in remission for over 3 years.Check my eligibility
What is being tested?
The trial is testing HPN217's safety, tolerability, and pharmacokinetics (how the drug moves through the body) in patients whose multiple myeloma has returned after treatment or hasn't responded to previous therapies.See study design
What are the potential side effects?
Specific side effects of HPN217 are not listed but generally may include typical reactions such as nausea, fatigue, allergic responses to the drug infusion itself and potential impacts on blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have recovered from the side effects of my previous treatments.
Select...
I've had 3 treatments for myeloma, including specific drugs, and can't tolerate or am not eligible for other beneficial treatments.
Select...
I am 18 years old or older.
Select...
My multiple myeloma has returned or didn't respond well to treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency and severity of treatment-emergent AEs (TEAEs) graded according to NCI CTCAE version 5.0 (ASTCT grading criteria for CRS and ICANS)
Number and severity of DLTs following treatment with HPN217
Secondary outcome measures
Best Overall Response (BOR)
Duration of response (DOR)
Incidence of ADAs against HPN217
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: HPN217 monotherapy dose escalationExperimental Treatment1 Intervention
HPN217 is IV administered once weekly for about 1 hour. Doses will vary between cohorts as MTD and/or RP2D[s] is being determined.
Group II: HPN217 dose escalation with extended dosing intervalsExperimental Treatment1 Intervention
HPN217 is IV administered either once bi-weekly or weekly for the first cycle followed by a bi-weekly schedule for about 1 hour. Doses will vary between cohorts as MTD and/or RP2D[s] is being determined.

Find a Location

Who is running the clinical trial?

Harpoon TherapeuticsLead Sponsor
3 Previous Clinical Trials
361 Total Patients Enrolled

Media Library

HPN217 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04184050 — Phase 1
Multiple Myeloma Research Study Groups: HPN217 dose escalation with extended dosing intervals, HPN217 monotherapy dose escalation
Multiple Myeloma Clinical Trial 2023: HPN217 Highlights & Side Effects. Trial Name: NCT04184050 — Phase 1
HPN217 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04184050 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment currently available for this research endeavor?

"As per the clinicaltrials.gov registry, this medical trial is currently enlisting volunteers and has been modified most recently on July 21st 2022 since its initial announcement in March of 2020."

Answered by AI

What is the current enrollment size of this clinical investigation?

"In order for this clinical trial to commence, Harpoon Therapeutics must recruit 70 suitable candidates. These participants will be enrolled from Swedish Medical Center in Seattle and Banner MD Anderson Cancer Centre in Gilbert, Arizona."

Answered by AI

What potential risks exist for patients taking HPN217?

"Applying a scale of 1-3, our analysts at Power believe HPN217's safety to be an estimated score of 1 due to the restricted amount of supporting evidence for its efficacy and security."

Answered by AI

In how many locations is this clinical research accessible?

"Patients can take part in this clinical trial at the Swedish Medical Center, Banner MD Anderson Cancer Centre, and Colorado Blood Cancer Institute. Additionally, there are 11 additional sites available."

Answered by AI

Is this research project enrolling individuals above the age of eighty-five?

"According to the criteria for eligibility, potential participants in this clinical trial should have a minimum age of 18 and an upper limit of 100 years old."

Answered by AI

What criteria must an individual meet to be eligible for the clinical trial?

"This trial is recruiting 70 participants, ranging from 18 to 100 years old, with documented RRMM and a serum M-protein count of 0.5 g/dL or higher. Other requirements include having received at least 3 prior treatments (including proteasome inhibitor therapy and immune modulatory drug treatment), an abnormal FLC ratio (<0.26 or >1.65) and resolution of any acute effects to baseline severity according to CTCAE version 5.0 Grade ≤1 standards"

Answered by AI
~19 spots leftby Mar 2025